Almirall to Present New Biologics Data for Psoriasis and Dermatitis at EADV Congress, Celebrates 80 Years of Innovation

Almirall, S.A. (ALM), a global pharmaceutical company specializing in medical dermatology, has announced its participation in the 33rd Congress of the European Academy of Dermatology and Venereology (EADV) in Amsterdam from September 25 to 28, 2024. This year is particularly notable for Almirall as the company celebrates its 80th anniversary, highlighting eight decades of innovation and dedication to improving health outcomes worldwide.

During the congress, Almirall will present 34 abstracts showcasing their latest research on several dermatological treatments. These include lebrikizumab for treating moderate-to-severe atopic dermatitis in both adolescents and adults, tildrakizumab, and Almirall’s CAL/BDP cream for moderate-to-severe plaque psoriasis in adults, as well as tirbanibulin for actinic keratosis. The company will also host two symposia aimed at providing platforms for experts to discuss current data, exchange insights, and facilitate in-depth discussions on the treatment of these chronic conditions using advanced biologics.

Significant findings will be shared from the POSITIVE clinical study, focused on the treatment of adults with moderate-to-severe plaque psoriasis with tildrakizumab over a 52-week period. This study is groundbreaking, as it is the first clinical trial in dermatology to utilize the WHO-5 Wellbeing Index as a primary endpoint. The WHO-5 Wellbeing Index is a validated questionnaire that measures health-related subjective psychological wellbeing across various chronic diseases. Sub-analyses presented at the congress will underscore the effectiveness of tildrakizumab on both skin symptoms and overall wellbeing.

One of the key symposiums titled "Advancing Psoriasis Management for Long-Term Patient Outcomes" will feature distinguished experts like Prof. Dr. Diamant Thaçi from the University of Lübeck, Prof. Dr. Ulrich Mrowietz from the University Medical Center Schleswig-Holstein, and Prof. Anna López Ferrer from the Hospital de la Santa Creu i Sant Pau in Barcelona. This discussion will focus on the importance of individualized treatments, the latest real-world evidence, and practical strategies for successfully managing psoriasis, with opportunities for interactive dialogue with leading specialists.

In addition to psoriasis, Almirall will present new data on lebrikizumab, a biologic approved for the treatment of moderate-to-severe atopic dermatitis. The late-breaking presentation will cover data spanning three years of continuous treatment, including rates of absolute endpoints and its effectiveness in patients who are inadequately controlled or ineligible for cyclosporine. The symposium titled "Precision in AD: How Lebrikizumab is Changing the Treatment Paradigm" will include experts such as Marjolein Bruin-Weller from the National Expertise Center for Atopic Dermatitis at the University Medical Center Utrecht, Andrew Blauvelt from Portland, US, and Sascha Gerdes from the Center for Inflammatory Skin Diseases of the University Medical Center Schleswig-Holstein Campus Kiel. Discussions will concentrate on the clinical impact of lebrikizumab, providing participants with a chance to engage with leading experts.

The year 2024 is a milestone for Almirall, marking the company's 80th anniversary. Over the past eight decades, Almirall has amassed a rich history in the pharmaceutical industry with a strong emphasis on medical dermatology. This milestone signifies the company’s continued commitment to innovation and delivering impactful solutions that improve patients’ lives. Almirall's success in medical dermatology is supported by its close collaborations with the dermatology community and its patient-centric approach. As it celebrates its 80th anniversary, Almirall reaffirms its dedication to advancing skin science and developing novel treatments to benefit patients and the broader dermatology community globally.